法明制药

最新新闻

• CCORF Initiates Pharming Group(PHAR.US) With Buy Rating, Announces Target Price $37
  \u5e02\u573a\u8d44\u8baf · 2026/4/10
• 评级变动
  TR | OpenAI - 4o Maintains Pharming Group(PHAR.US) With Hold Rating, Cuts Target Price to $13
  \u5e02\u573a\u8d44\u8baf · 2025/8/12
• CCORF Maintains Pharming Group(PHAR.US) With Buy Rating, Maintains Target Price $38
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• 评级变动
  Pharming Group (PHAR) Receives a Buy From H.C. Wainwright
  TipRanks · 2026/1/28
• 公司公告
  EXTRAWELL PHAR: FORM OF PROXY FOR USE BY SHAREHOLDERS AT THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 28 AUGUST 2026 AT 11:00 A.M.
  HKEX · 2026/7/30
• 公司公告
  EXTRAWELL PHAR: FORM OF PROXY FOR USE BY SHAREHOLDERS AT THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 22 AUGUST 2025 AT 11:00 A.M.
  HKEX · 2025/7/28
• CCORF Maintains Pharming Group(PHAR.US) With Buy Rating, Raises Target Price to $38
  \u5e02\u573a\u8d44\u8baf · 2026/8/3
• 评级变动
  Oppenheimer Maintains Pharming Group(PHAR.US) With Buy Rating, Cuts Target Price to $40
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• 评级变动
  Oppenheimer Maintains Pharming Group(PHAR.US) With Buy Rating, Raises Target Price to $42
  \u5e02\u573a\u8d44\u8baf · 2025/11/7
• H.C. Wainwright Maintains Pharming Group(PHAR.US) With Buy Rating, Maintains Target Price $37
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• 评级变动
  H.C. Wainwright Remains a Buy on Pharming Group (PHAR)
  TipRanks · 2025/11/7
• 公司公告
  INNOVATIVE PHAR: RETIREMENT OF AUDITOR; AND WITHDRAWAL OF RESOLUTION NO. 3 AT THE ANNUAL GENERAL MEETING TO BE HELD ON THURSDAY, 29 AUGUST 2024
  HKEX · 2024/8/14
• 评级变动
  Oppenheimer Maintains Pharming Group(PHAR.US) With Buy Rating, Maintains Target Price $42
  \u5e02\u573a\u8d44\u8baf · 2026/2/4
• 公司公告
  EXTRAWELL PHAR: FORM OF PROXY FOR SPECIAL GENERAL MEETING TO BE HELD ON TUESDAY, 15 OCTOBER 2024 AT 11:00 A.M.
  HKEX · 2024/9/26
• 公司公告
  EXTRAWELL PHAR: FORM OF PROXY FOR SPECIAL GENERAL MEETING TO BE HELD ON FRIDAY, 28 MARCH 2025 AT 11:00 A.M.
  HKEX · 2025/3/12
• 评级变动
  Oppenheimer Maintains Pharming Group(PHAR.US) With Buy Rating, Cuts Target Price to $41
  \u5e02\u573a\u8d44\u8baf · 2026/3/13
• 评级变动
  TR | OpenAI - 4o Upgrades Pharming Group(PHAR.US) to Buy Rating, Raises Target Price to $13.5
  \u5e02\u573a\u8d44\u8baf · 2025/8/6
• 评级变动
  Oppenheimer Maintains Pharming Group(PHAR.US) With Buy Rating, Raises Target Price to $41
  \u5e02\u573a\u8d44\u8baf · 2025/8/1
• CCORF Maintains Pharming Group(PHAR.US) With Buy Rating, Maintains Target Price $37
  \u5e02\u573a\u8d44\u8baf · 2026/6/23
• 评级变动
  TR | OpenAI - 4o Downgrades Pharming Group(PHAR.US) to Hold Rating, Raises Target Price to $14.5
  \u5e02\u573a\u8d44\u8baf · 2025/8/11

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。